Dienstag,
27.02.2018 13:00
von
GlobeNewswire
| Aufrufe: 125
uniQure to Participate in Multiple Conferences in March
Ein Mann liest Wirtschaftsnachrichten (Symbolbild).
pixabay.com
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical, scientific and investor conferences during March.
- ISBiotech 8th Spring Meeting, March 3 - 5, 2018 at the Hilton Norfolk the Main in Norfolk, VA
- Jacek Lubelski, Ph.D., director of vector & process development, will be presenting on Baculovirus Expression Technology, on Wednesday, March 7th at 11:15 a.m. ET.
- Thrombosis and Hemostasis Societies of North America (THSNA) Biennial Meeting, March 8 - 10, 2018 at the Marriott Marquis in San Diego, CA
- Eileen Sawyer, Ph.D., director of global medical affairs, will be presenting "Endogenous FIX Expression and Reduced Annual Bleed Rate Following AMT-060 (AAV-hFIX) in Adults With Severe or Moderate-Severe Hemophilia B: Interim Results up to 2 Years from a Phase I/II Dose-Escalation Study" on Friday, March 9th at 10:30 a.m. PT.
- BIO-Europe Spring, March 12 - 14, 2018 at the RAI Convention Center in Amsterdam, the Netherlands
- Sander van Deventer, M.D., Ph.D., chief scientific officer and general manager, Amsterdam, will be participating in a panel discussion titled, "New Advances in Gene Therapy: Next Generation Technologies" on Tuesday, March 13th at 2:00 p.m. CET.
- 38th Annual Cowen & Co. Global Healthcare Conference, March 12 -14, 2018 at the Boston Marriott Copley Place in Boston, MA
- Matt Kapusta, chief executive officer, will be presenting a corporate update on Wednesday, March 14th at 8:40 a.m. ET. The live webcast can be accessed by the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.
- In addition, company management will be hosting meetings with institutional investors throughout the conference.
- Spring Symposium of the Netherlands Society of Gene and Cell Therapy (NVGCT), March 15 -16, 2018 at Congrescentrum De Werelt in Lunteren, the Netherlands
- Dr. van Deventer will be presenting on uniQure's approach in gene therapy on Thursday, March 15th at 3:00 p.m. CET.
- Barclays Global Healthcare Conference, March 13 - 15, 2018 at the Loews Miami Beach Hotel in Miami, FL
- Steve Zelenkofske, D.O., chief medical officer, will be presenting a corporate overview on Thursday, March 15th at 2:05 p.m. ET, followed by a fireside chat. The live webcast can be accessed by the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.
- In addition, company management will be hosting meetings with institutional investors throughout the day.
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington's disease and cardiovascular diseases.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via Globenewswire
ARIVA.DE Börsen-Geflüster
Werbung
Mehr Nachrichten zur uniQure Aktie kostenlos abonnieren
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis:
ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen.
Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich
dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch
eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link
„Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für
diese Inhalte ist allein der genannte Dritte.
Andere Nutzer interessierten sich auch für folgende News
24.04.24 - PR Newswire
24.04.24 - PR Newswire
24.04.24 - PR Newswire